OOIR: Observatory of International Research

Papers

(The TQCC of Blood Reviews is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting	259
Interplay between platelets and coagulation	164
Targeting MCL-1 in hematologic malignancies: Rationale and progress	131
Coagulation and anticoagulation in COVID-19	125
Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system	116
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes	108
The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis	98
Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents	86
The looming storm: Blood and cytokines in COVID-19	65
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions	64
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved	63
Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment	59
A review of FLT3 inhibitors in acute myeloid leukemia	57
Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map	55
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities	54
Role of inflammation in the biology of myeloproliferative neoplasms	50
COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research	49
Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions	48
Understanding terminal erythropoiesis: An update on chromatin condensation, enucleation, and reticulocyte maturation	46
Illness and prognostic understanding in patients with hematologic malignancies	42
Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities	41
Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies	40
Current state and next-generation CAR-T cells in multiple myeloma	40
Current management strategies for polycythemia vera and essential thrombocythemia	39
Inherited thrombocytopenias: an updated guide for clinicians	38

Discussing investigational AAV gene therapy with hemophilia patients: A guide	38
Current and emerging strategies for management of myelodysplastic syndromes	35
Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer	32
Second primary malignancies in multiple myeloma: A review	32
Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature	29
IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly	29
Targeting the gut microbiome: An emerging trend in hematopoietic stem cell transplantation	28
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options	27
Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies	25
Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models	25
Revving the CAR – Combination strategies to enhance CAR T cell effectiveness	25
The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma	24
CLL update 2022: A continuing evolution in care	24
Heterogeneity of congenital afibrinogenemia, from epidemiology to clinical consequences and management	24
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?	23
Complement activation in COVID-19 and targeted therapeutic options: A scoping review	23
Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?	22
The emerging role of red blood cells in cytokine signalling and modulating immune cells	22
It takes two to thrombosis: Hemolysis and complement	22
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag	22
Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways	22
Ex vivo expansion of hematopoietic stem cells: Finally transitioning from the lab to the clinic	22
Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential	21
Hormonal replacement therapy in adolescents and young women with chemo- or radio-induced premature ovarian insufficiency: Practical recommendations	21
Transfusion-related acute lung injury (TRALI): Potential pathways of development, strategies for prevention and treatment, and future research directions	21
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers	21
The critical roles of iron during the journey from fetus to adolescent: Developmental aspects of iron homeostasis	21
Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentation	21
l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?	21
Use of molecularly-cloned haematopoietic growth factors in persons exposed to acute high-dose, high-dose rate whole-body ionizing radiations	21
Immune thrombocytopenia: A review of upfront treatment strategies	21
Hemophilia treatment in 2021: Choosing the”optimal” treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians	21
Artificial intelligence in hematological diagnostics: Game changer or gadget?	20
Optimising prophylaxis in haemophilia A: The ups and downs of treatment	20
Management of challenging myelofibrosis after JAK inhibitor failure and/or progression	20
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity	19
Magnesium: The overlooked electrolyte in blood cancers?	19
Metabolic regulation of the bone marrow microenvironment in leukemia	19
A review on how to do hematology consults during COVID-19 pandemic	19
Hypereosinophilic syndromes – An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment	18
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option	18
Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations	18
AML and the art of remission maintenance	18
A new frontier in Fanconi anemia: From DNA repair to ribosome biogenesis	18
Diagnosis of infectious diseases in immunocompromised hosts using metagenomic next generation sequencing-based diagnostics	17
Revisiting Richter transformation in the era of novel CLL agents	17
The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia	17
Germline genetic factors in the pathogenesis of myeloproliferative neoplasms	17
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management	16
Peripheral neuropathy in hematologic malignancies – Past, present and future	16

The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation	16
Determinants of severity in sickle cell disease	16
A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia	16